Notícias e Atividades da Corbus Pharmaceuticals

Corbus Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Corbus Pharmaceuticals é uma empresa listada sob o símbolo CRBP (US).

Veja o organograma con seus 11 executivos principais

Biografias mais buscadas da Corbus Pharmaceuticals

• Yuval Cohen, Chief Executive Officer and Director
• Alan Holmer, Chairman of the Board
• Rachelle Jacques, Director

Recentes movimentos de executivos em Corbus Pharmaceuticals

• Peter Salzmann, Director, deixará a Companhia em 31 de mar. de 2025  (Notícia publicada em 26 de março de 2025).
• Ian Hodgson, ingressou na Companhia como Chief Operating Officer  (Notícia publicada em 26 de março de 2025).
• Winston Kung, ingressou na Companhia como Director  (Notícia publicada em 21 de agosto de 2024).

Criar um alerta
para seguir os movimentos de executivos da Corbus Pharmaceuticals.

Corbus Pharmaceuticals possui 1.833 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Corbus Pharmaceuticals

• Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
• Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
• Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
• Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
• CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
• Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
• Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
• Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
• FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
• Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
• View more press releases Close

Redes sociais sobre Corbus Pharmaceuticals

• Corbus Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Corbus Pharmaceuticals na LinkedIn, Twitter e YouTube